KR20130060682A - Cosmetic composition of oil in water type containing fructose 1,6-diphosphate - Google Patents
Cosmetic composition of oil in water type containing fructose 1,6-diphosphate Download PDFInfo
- Publication number
- KR20130060682A KR20130060682A KR1020110126879A KR20110126879A KR20130060682A KR 20130060682 A KR20130060682 A KR 20130060682A KR 1020110126879 A KR1020110126879 A KR 1020110126879A KR 20110126879 A KR20110126879 A KR 20110126879A KR 20130060682 A KR20130060682 A KR 20130060682A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- diphosphate
- skin
- fructose
- comparative example
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 title claims abstract description 36
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 title claims abstract description 26
- 239000002537 cosmetic Substances 0.000 title abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 15
- 229920001202 Inulin Polymers 0.000 claims description 11
- 229940029339 inulin Drugs 0.000 claims description 11
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims description 10
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 claims description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229940045898 sodium stearoyl glutamate Drugs 0.000 claims description 10
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 claims description 10
- 229920000058 polyacrylate Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 6
- 230000037303 wrinkles Effects 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 abstract description 12
- 239000007764 o/w emulsion Substances 0.000 abstract description 5
- 230000000052 comparative effect Effects 0.000 description 43
- 238000009472 formulation Methods 0.000 description 19
- 239000002562 thickening agent Substances 0.000 description 18
- 239000004094 surface-active agent Substances 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- -1 fructose 1,6-diphosphate compound Chemical class 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000008719 thickening Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- LVQSCKUKDKAQGO-UHFFFAOYSA-L disodium;diiodide Chemical compound [Na+].[Na+].[I-].[I-] LVQSCKUKDKAQGO-UHFFFAOYSA-L 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- SDPBXXCJVDQPIQ-UHFFFAOYSA-N hexadecyl hexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC SDPBXXCJVDQPIQ-UHFFFAOYSA-N 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 230000015227 regulation of liquid surface tension Effects 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- XBNFOAOCJWQKPX-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;octadecanoic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O XBNFOAOCJWQKPX-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 프룩토오스 1,6-디포스페이트를 포함하는 수중유형 화장료용 조성물, 보다 상세하게는 프룩토오스 1,6-디포스페이트를 함유하면서도 유화 안정성 및 사용감이 우수한 수중유형 조성물에 관한 것이다.The present invention relates to an oil-in-water cosmetic composition comprising fructose 1,6-diphosphate, and more particularly, to an oil-in-water composition containing fructose 1,6-diphosphate and having excellent emulsion stability and usability.
Description
본 발명은 프룩토오스 1,6-디포스페이트를 포함하는 수중유형 화장료용 조성물, 보다 상세하게는 프룩토오스 1,6-디포스페이트를 함유하면서도 유화 안정성 및 사용감이 우수한 수중유형조성물에 관한 것이다.The present invention relates to an oil-in-water cosmetic composition comprising fructose 1,6-diphosphate, and more particularly, to an oil-in-water composition containing fructose 1,6-diphosphate and having excellent emulsion stability and usability.
프룩토오스 1,6-디포스페이트(Fructose 1,6-Diphosphate; FDP)는 허혈/재관류(Ischemia/reperfusion)와 같은 산화적 손상으로부터 조직을 보호하거나, 적출된 장기의 ATP 고갈에 의한 손상을 방지하기 위해 사용되어 왔다. 이러한 프룩토오스 1,6-디포스페이트가 외과수술 등과 같은 급격한 환경에서 심장 등의 조직을 효과적으로 보호하는 것과 같이, 자외선과 같은 산화적 손상을 유발하는 환경에서 피부세포를 보호할 수 있는지, 더 나아가 이러한 효과가 직접적으로 피부노화현상을 완화 혹은 지연시킬 수 있는지에 대해서 피부세포뿐만 아니라 동물 및 사람을 대상으로 다각도의 실험을 진행하여 프룩토오스 1,6-디포스페이트는 자외선에 의한 피부세포 손상을 억제할 뿐만 아니라 이로 인한 피부노화현상을 현저히 억제 혹은 개선시키는 결과를 얻을 수 있었다.Fructose 1,6-Diphosphate (FDP) protects tissues from oxidative damage, such as ischemia / reperfusion, or prevents damage from ATP depletion of isolated organs It has been used to Whether fructose 1,6-diphosphate can protect skin cells in an environment that causes oxidative damage such as ultraviolet rays, such as effectively protecting tissues such as the heart in a rapid environment such as surgery. Whether these effects can directly alleviate or delay skin aging can be achieved by multi-faceted experiments on animals and humans as well as skin cells.Fructose 1,6-diphosphate can be used to protect skin cells from UV damage. In addition to suppressing, it was possible to significantly reduce or improve skin aging.
그러나 프룩토오스 1,6-디포스페이트는 분자 구조 내에 포스페이트 염을 갖는 강한 염의 성질을 갖는 물질로서, 이온성 고분자 증점제의 증점 능력과 수중유 제형의 안정도를 크게 저하시키기 때문에 수중유형 제형에서의 사용이 크게 제한되어 왔다.However, fructose 1,6-diphosphate is a substance having a strong salt property with a phosphate salt in its molecular structure, which greatly reduces the thickening ability of the ionic polymer thickener and the stability of the oil-in-water formulation. This has been greatly limited.
이에, 최근에는 상기의 프룩토오스 1,6-디포스페이트를 함유한 수중유 제형의 안정도를 증대시키기 위한 방법으로서 고함량의 왁스를 첨가하여 화장료를 증점시키고 유화를 안정화 시키는 방법, 잔탄검, 셀룰로오스검, 하이드록시에칠셀룰로오스 등 셀룰로오스 계열의 점증제를 사용하여 화장료를 증점시키고 유화를 안정화시키는 방법 등이 제안되었다.Recently, as a method for increasing the stability of the oil-in-water formulation containing fructose 1,6-diphosphate, a method of thickening cosmetics and stabilizing emulsification by adding a wax of high content, xanthan gum, cellulose A method of thickening cosmetics and stabilizing emulsification using cellulose thickeners such as gum and hydroxyethyl cellulose has been proposed.
하지만 최근 제안된 상기한 방법들은 어느 것이나 다음과 같은 문제점을 가지고 있다. 즉, 고함량의 왁스를 첨가하는 방법은 왁스로서 화장료를 증점시키고 어느 정도의 유화 안정화 효과는 있는 것으로 알려져 있으나, 고함량의 왁스로 인한 화장료의 외관 불균일화, 수상 분리 현상 등이 야기될 수 있고 화장료의 사용감이 크게 저하되는 단점이 있으며, 왁스가 산화될 경우 변취, 변색의 문제 또한 야기할 수 있어 프룩토오스 1,6-디포스페이트를 함유한 수중유 제형의 안정화 방법으로 인정받지 못하고 있다.However, all of the above-mentioned methods have the following problems. That is, the method of adding a high content of wax is known to have a certain amount of emulsification and stabilizing effect as a wax as a wax, but the appearance of unevenness of the cosmetics due to the high content of wax, separation of the water phase may be caused. There is a disadvantage in that the feeling of use of cosmetics is greatly reduced, and if the wax is oxidized, it may also cause problems of discoloration and discoloration, and thus it is not recognized as a stabilization method of oil-in-water formulation containing fructose 1,6-diphosphate.
또한, 잔탄검, 셀룰로오스검, 하이드록시에칠셀룰로오스 등 셀룰로오스 계열의 점증제를 사용하는 방법은 비교적 프룩토오스 1,6-디포스페이트의 염에도 비교적 안정적인 증점 능력을 구현할 수 있기 때문에 유화 안정화에 도움을 줄 수 있으나, 셀룰로오스 계열 증점제 특유의 끈적이는 사용감과 겔링 현상으로 인하여 화장료의 사용감을 크게 저하시키며 셀룰로오스 계열의 점증제가 화장료의 방부력을 크게 저하시킨다는 문제점 또한 가지고 있다.In addition, the use of cellulose-based thickeners such as xanthan gum, cellulose gum, and hydroxyethyl cellulose helps to stabilize the emulsification because it can realize relatively stable thickening ability even with salts of fructose 1,6-diphosphate. However, due to the sticky feeling and gelling phenomenon peculiar to the cellulose thickener, the feeling of the cosmetics is greatly reduced, and the cellulose-based thickener also significantly reduces the antiseptic power of the cosmetics.
이에, 본 발명자들은 프룩토오스 1,6-디포스페이트를 안정하게 담지할 수 있는 수중유형 유화 제형에 대한 연구를 거듭한 결과, 프룩토오스 1,6-디포스페이트를 포함한 화장료 조성물의 안정성이 유지될 수 있는 최적의 제형 조건을 발견하고 본 발명을 완성하였다.Accordingly, the present inventors have conducted a study on an oil-in-water emulsion formulation capable of stably supporting fructose 1,6-diphosphate, and as a result, the stability of the cosmetic composition including fructose 1,6-diphosphate is maintained. Optimal formulation conditions have been found and the present invention has been completed.
따라서, 본 발명은 프룩토오스 1,6-디포스페이트를 함유하면서도 유화 안정성 및 사용감이 우수한 수중유형 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide an oil-in-water composition which contains fructose 1,6-diphosphate and is excellent in emulsion stability and usability.
상기 목적을 달성하기 위해, 본 발명은 프룩토오스 1,6-디포스페이트 화합물을 유효성분으로 함유하는 피부 외용제 조성물로서 계면활성제 및 증점제를 더 함유하는 것을 특징으로 하는 피부 외용제 조성물을 제공한다. In order to achieve the above object, the present invention provides a topical skin composition, further comprising a surfactant and a thickener as a topical skin composition containing a fructose 1,6-diphosphate compound as an active ingredient.
나아가, 본 발명은 프룩토오스 1,6-디포스페이트 화합물을 유효성분으로 함유하는 피부 외용제 조성물로서 세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트 계면활성제 조합을 포함하며, 증점제로서 폴리아크릴레이트크로스폴리머-6를 더 포함하는 것을 특징으로 하는 피부 외용제 조성물을 제공한다.Furthermore, the present invention is a composition for external application for skin containing fructose 1,6-diphosphate compound as cetearylglucoside / inulin lauryl carbamate or sodium stearoyl glutamate / glyceryl stearate citrate surfactant It provides a skin external composition, comprising a combination, further comprising polyacrylate crosspolymer-6 as a thickener.
본 발명은 화장료 조성물의 안정성이 유지될 수 있는 최적의 계면활성제, 점증제 조합을 설정함으로써, 프룩토오스 1,6-디포스페이트 화합물을 포함한 수중유형 제형으로 안정화된 피부 외용제 조성물을 제공할 수 있다. The present invention can provide a topical skin composition stabilized in an oil-in-water formulation containing a fructose 1,6-diphosphate compound by setting an optimum combination of surfactants and thickeners in which the stability of the cosmetic composition can be maintained. .
또한, 상기 조성물 내에서 유효성분인 프룩토오스 1,6-디포스페이트 화합물의 포스페이트 염에 의하여 저해되는 에멀젼의 안정도는 강력한 계면활성력을 갖는 계면활성제와 더불어 염에 대한 계면의 안정도를 높여줄 수 있는 계면활성제를 포함함으로써 안정도를 개선시킬 수 있으며, 염에 의하여 증점력이 저해되지 않는 증점제를 포함하여 조성물의 점도를 높여줌으로써 보조적으로 상기 수중유형의 안정도를 개선한 항노화용 피부 외용제 조성물을 제공할 수 있다. In addition, the stability of the emulsion inhibited by the phosphate salt of the fructose 1,6-diphosphate compound as an active ingredient in the composition can increase the stability of the interface to the salt along with a surfactant having a strong surfactant activity. It is possible to provide an anti-aging skin external composition for improving the stability of the oil-in-water type by improving the stability of the oil-in-water type by including a thickening agent that can improve the stability by including a surfactant that is not inhibited by the salt thickening power. Can be.
본 발명은 프룩토오스 1,6-디포스페이트 화합물을 유효성분으로 함유하는 피부 외용제 조성물로서 계면활성제 및 증점제를 더 포함하는 것을 특징으로 하는 피부 외용제 조성물을 제공한다.
The present invention provides an external preparation composition for skin, further comprising a surfactant and a thickener as an external preparation composition containing a fructose 1,6-diphosphate compound as an active ingredient.
이하, 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described more specifically.
본 발명의 유효성분인 프룩토오스 1,6-디포스페이트 (Fructose 1,6-Diphosphate; FDP)는 자외선과 같은 산화적 손상을 유발하는 환경에서 피부 세포를 보호할 수 있고, 더 나아가 직접적으로 피부 노화 현상을 완화 혹은 지연시킬 수 있다.Fructose 1,6-Diphosphate (FDP), an active ingredient of the present invention, can protect skin cells in an environment causing oxidative damage such as ultraviolet rays, and further directly May alleviate or delay aging.
즉, 프룩토오스 1,6-디포스페이트는 강력한 항산화 효과를 갖고 있으며, 이를 통하여 산화를 유발하는 자유라디칼 등을 상쇄시켜 노화가 진행되는 것을 방지하는 효과를 가질뿐만 아니라 주름개선기능성 물질로서 주름개선효과를 통하여 피부 노화 현상을 완화시켜준다.In other words, fructose 1,6-diphosphate has a strong antioxidant effect, through which it has the effect of preventing the aging progress by offsetting free radicals that cause oxidation, and also improve wrinkles as a functional material to improve wrinkles It helps relieve skin aging.
보다 구체적으로, 프룩토오스 1,6-디포스페이트 는 프로스타글란딘 E2 합성과 COX-2 발현을 감쇄시켜 항염효과를 나타내며, MMP 발현을 억제하여 주름 억제 효과, 콜라겐 합성을 증대시켜 피부 탄력 증진, 히스타민 분비 억제를 통한 자극 완화 효과, 케라티노사이트 분화 조절을 통한 피부 보습 효과, ATP 합성 증대를 통한 피부 활력 증진 효과를 통하여 복합적인 피부 노화 개선 효과를 나타낸다.More specifically, fructose 1,6-diphosphate exhibits anti-inflammatory effect by attenuating prostaglandin E2 synthesis and COX-2 expression, and inhibiting MMP expression to increase wrinkle suppression and collagen synthesis to enhance skin elasticity and release histamine It exhibits complex skin aging improvement through stimulating mitigation through inhibition, skin moisturizing through regulating keratinocyte differentiation, and skin vitality through increasing ATP synthesis.
본 발명의 유효성분인 프룩토오스 1,6-디포스페이트는 조성물 총 중량에 대하여 0.001~ 7.0중량%로 함유됨이 바람직하다. 이는 0.001중량% 미만이면 항노화, 항산화 효능이 미미하게 되며, 7.0중량% 초과이면 다량의 포스페이트 염이 화장료 제형의 불안정을 초래하기 때문이다.Fructose 1,6-diphosphate as an active ingredient of the present invention is preferably contained in 0.001 to 7.0% by weight based on the total weight of the composition. This is because less than 0.001% by weight of the anti-aging, antioxidant effects are insignificant, and more than 7.0% by weight of the large amount of phosphate salts cause instability of the cosmetic formulation.
본 발명의 피부 외용제 조성물 내에서 유효성분인 프룩토오스 1,6-디포스페이트 화합물의 포스페이트 염에 의하여 저해되는 에멀젼의 안정도는 일반적으로 화장품에 사용하는 모든 범위의 수중유형 계면활성제 및 증점제를 더 사용함으로써 안정도를 향상시킬 수 있다. 본 발명에 사용가능한 계면활성제로는 피이지-100스테아레이트, 소르비탄스테아레이트, 소르비탄세스퀴올리에이트, 피이지-40스테아레이트, 폴리소르베이트 60, 슈크로오스스테아레이트, 폴리글리세릴-3메칠글루코오스디스테아레이트, 세테아릴글루코사이드, 아라키딜글루코사이드, C12-20알킬글루코사이드, 이눌린라우릴카바메이 등이 있다. 또한, 본 발명에 사용하능한 증점제로는 셀룰로오스검, 카보머, 하이드록시에칠셀룰로오스, 폴리비닐알코올, 피브이피, 잔탄검, 아크릴레이트/C10-30알킬아크릴레이트크로스폴리머, 소듐폴리아크릴레이트, 암모늄아크릴로일디메칠타우레이트/브이피코폴리머, 하이드록시프로필스타치포스페이트, 폴리아크릴레이트-13, 하이드록시에칠아크릴레이트/소듐아크릴로일디메칠타우레이트코폴리머, 피이지-240/에이치디아이코폴리머 비스데실테스라세스-2 에틸, 폴리아크릴릭애씨드 등이 있다. The stability of the emulsion inhibited by the phosphate salt of the fructose 1,6-diphosphate compound as an active ingredient in the external preparation composition for skin of the present invention is generally used in all types of oil-in-water surfactants and thickeners used in cosmetics. By this, stability can be improved. Surfactants usable in the present invention include: Fiji-100 Stearate, Sorbitan Stearate, Sorbitan Sesquioleate, Fiji-40 Stearate, Polysorbate 60, Sucrose Stearate, Polyglyceryl- 3-methylglucose distearate, cetearyl glucoside, arachidyl glucoside, C12-20 alkyl glucoside, inulin lauryl carbame and the like. In addition, thickeners usable in the present invention include cellulose gum, carbomer, hydroxyethyl cellulose, polyvinyl alcohol, FV, xanthan gum, acrylate / C10-30 alkyl acrylate crosspolymer, sodium polyacrylate, Ammonium Acryloyl Dimethyl Taurate / V-Picopolymer, Hydroxypropyl Starch Phosphate, Polyacrylate-13, Hydroxyethylacrylate / Sodium Acryloyl Dimethyl Taurate Copolymer, Fiji-240 / H-Diacico Polymer bisdecyltesraceses-2 ethyl, polyacrylic acid and the like.
특히, 본 발명의 피부 외용제 조성물 내에서 유효성분인 프룩토오스 1,6-디포스페이트 화합물의 포스페이트 염에 의하여 저해되는 에멀젼의 안정도는 강력한 계면활성력을 갖는 계면활성제와 더불어 염에 대한 계면의 안정도를 높여줄 수 있는 계면활성제의 조합으로 세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트를 더 함유함으로써 안정도를 극대화시킬 수 있고, 염에 의하여 증점력이 저해되지 않는 이온성 증점제인 폴리아크릴레이트크로스폴리머-6을 더 함유함으로써 조성물의 점도를 높여주어 보조적으로 상기 수중유형 에멀젼 제형의 안정도를 극대화시킬 수 있어 바람직하다.In particular, the stability of the emulsion inhibited by the phosphate salt of the fructose 1,6-diphosphate compound as an active ingredient in the external preparation composition for skin of the present invention, along with the surfactant having a strong surfactant activity, the stability of the interface to the salt It is a combination of surfactants that can increase the content of cetearyl glucoside / inulin lauryl carbamate or sodium stearoyl glutamate / glyceryl stearate citrate to maximize the stability, salt It is preferable to further contain polyacrylate crosspolymer-6, an ionic thickener that is not inhibited, to increase the viscosity of the composition and to assist in maximizing the stability of the oil-in-water emulsion formulation.
본 발명에서 사용되는 계면활성제 조합 중 세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트 계면활성제 조합에 있어서, 세테아릴글루코사이드 또는 소듐스테아로일글루타메이트는 조성물 총 중량에 대하여 0.1~10.0중량%, 이눌린라우릴카바메이트 또는 글리세릴스테아레이트시트레이트는 조성물 총 중량에 대하여 0.1~10.0 중량%로 함유됨이 바람직하다. 이는 각각 0.1중량% 미만이면 계면활성 능력이 나타나지 않게 되고, 10.0중량% 초과이면 화장료 제형의 사용감과 제형 안정성을 저해하기 때문이다. Among the surfactant combinations used in the present invention, cetearylglucoside / inulin lauryl carbamate or sodium stearoyl glutamate / glyceryl stearate citrate surfactant combination, the cetearyl glucoside or sodium stearoyl glutamate composition 0.1-10.0 wt% with respect to the total weight, inulin lauryl carbamate or glyceryl stearate citrate is preferably contained 0.1-10.0 wt% with respect to the total weight of the composition. This is because less than 0.1% by weight of each of the surface active ability does not appear, and more than 10.0% by weight inhibits the feeling of use and formulation stability of the cosmetic formulation.
본 발명의 증점제는 조성물 총 중량에 대하여 0.1~5.0중량%로 함유됨이 바람직하다. 이는 0.1중량% 미만이면 증점 효과와 유화 안정 효과가 나타나지 않게 되고, 5.0중량% 초과이면 높은 점도로 인하여 화장료 제형의 제조 생산성을 크게 저해하기 때문이다.The thickener of the present invention is preferably contained in 0.1 to 5.0% by weight relative to the total weight of the composition. This is because if less than 0.1% by weight, the thickening effect and the emulsion stability effect does not appear, and if it is more than 5.0% by weight, it greatly inhibits the production productivity of the cosmetic formulation due to the high viscosity.
본 발명에 의한 피부 외용제 조성물은 당업계에 통상적으로 사용하는 하나 이상의 무독성, 약제학적으로 허용 가능한 담체, 보조제, 희석액 또는 다른 활성 성분을 포함할 수 있다. 본 발명에 의한 피부 외용제 조성물은 약제학적으로 허용 가능한 담체 및 부형제를 이용하여 공지의 방법으로 제제화될 수 있다.The topical skin composition according to the present invention may comprise one or more non-toxic, pharmaceutically acceptable carriers, adjuvants, diluents or other active ingredients conventionally used in the art. The external preparation composition for skin according to the present invention may be formulated by a known method using a pharmaceutically acceptable carrier and excipient.
구체적인 예를 들면 연고, 겔, 크림, 패취 또는 분무제 등의 외용제 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 제형화하여 사용할 수 있으며, 이들 각 제형은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 발명자에 의해 용이하게 선정될 수 있다.Specific examples may be formulated and used in any form suitable for pharmaceutical preparations, including external preparations such as ointments, gels, creams, patches or sprays, and each of these formulations may be formulated with various bases necessary and appropriate for the formulation thereof. It may contain additives, and the kind and amount of these components can be easily selected by the inventor.
또한, 본 발명에 의한 피부 외용제 조성물이 화장료로 제형화될 경우, 그 제형에 있어서 특별히 한정되는 바가 없으며 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩 등의 제형을 가질 수 있다.
In addition, when the external composition for skin preparations according to the present invention is formulated as a cosmetic, it is not particularly limited in the formulation, softening longevity, astringent longevity, nourishing longevity, eye cream, nourishing cream, massage cream, cleansing cream, cleansing foam, It may have a formulation such as cleansing water, powder, essence or pack.
이하, 본 발명을 구체적으로 설명하기 위해 실시예를 들어 상세하게 설명하기로 한다. 그러나 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.
Hereinafter, the present invention will be described in detail with reference to Examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
[실시예 1~6와 비교예 1~12][Examples 1-6 and Comparative Examples 1-12]
하기 표 1~3에 조성으로 본 발명에 따른 화장료 조성물(실시예 1~6)과 이와 비교하기 위한 화장료 조성물(비교예 1~12)을 제조하였다. In Tables 1 to 3, cosmetic compositions (Comparative Examples 1 to 12) for comparison with the cosmetic compositions according to the present invention (Examples 1 to 6) were prepared.
실시예 1~6은 본 발명에 따라 제조한 프룩토오스 1,6-디포스페이트 화합물을 유효성분으로 함유하는 피부 외용제 조성물로서 세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트 계면활성제 조합을 포함하며, 증점제로서 폴리아크릴레이트크로스폴리머-6를 포함하는 화장료 조성물이며, 비교예 1~4는 상기 제시된 계면활성제 조합이 아닌 한 가지 성분만을 이용하여 제조한 화장료 조성물이다. 비교예 5~6 는 상기 제시된 계면활성제 조합이 아닌 다른 종류의 계면활성제 조합을 사용하여 제조한 화장료 조성물이며, 비교예 7~12 는 본 발명에서 제시한 점증제인 폴리아크릴레이트크로스폴리머-6이 아닌 다른 종류의 고분자 점증제를 사용한 화장료 조성물이다.
Examples 1 to 6 are external skin composition containing fructose 1,6-diphosphate compound prepared according to the present invention as an active ingredient cetearyl glucoside / inulin lauryl carbamate or sodium stearoyl glutamate / glycerol A cosmetic composition comprising a reel stearate citrate surfactant combination and comprising a polyacrylate crosspolymer-6 as a thickener, and Comparative Examples 1 to 4 are cosmetics prepared using only one component other than the above-described surfactant combination. Composition. Comparative Examples 5 to 6 are cosmetic compositions prepared using a combination of surfactants other than the above-described surfactant combinations, and Comparative Examples 7 to 12 are not polyacrylate crosspolymer-6, which is a thickener of the present invention. It is a cosmetic composition using another kind of polymeric thickener.
<제조방법><Manufacturing Method>
1) 상기 유상 성분들을 비커에 칭량한 뒤 75℃까지 가온하여 완전히 녹였다.1) The oily ingredients were weighed in a beaker and warmed to 75 ° C to completely dissolve.
2) 상기 수상 성분들을 별도의 용기에서 70℃까지 가온하여 완전히 녹였다.2) The aqueous phase components were completely dissolved by heating to 70 ° C. in a separate vessel.
3) 상기 2)의 수상 성분들의 혼합물을 호모지나이져로 옮기고 분당회전수(rpm)를 천천히 높이면서 상기 1)의 유상 성분들의 혼합물에 투입하였다.3) The mixture of the aqueous phase components of 2) was transferred to a homogenizer and added to the mixture of oily components of 1) while slowly increasing the rpm.
4) 상기 3)의 혼합물을 5분 정도 7,200rpm으로 혼합한 뒤, 혼합상의 온도가 약 50℃일 때, 프룩토오스 1,6-디포스페이트를 투입하여 화장료를 제조하였다.
4) After mixing the mixture of 3) at 7,200rpm for about 5 minutes, when the temperature of the mixed phase is about 50 ℃, fructose 1,6-diphosphate was added to prepare a cosmetic.
[시험예 1] 점도 평가Test Example 1 Viscosity Evaluation
실시예 1~6 및 비교예 1~12의 화장료 조성물의 점도를 측정하여 그 결과를 하기 표 4에 나타내었다. 이때, 점도는 모든 샘플을 30℃에서 약 2시간 방치 후 브룩필드 점도계(Brookfield viscometer)를 사용하여 3번 스핀들로 12rpm에서 2분에 측정하였다.The viscosity of the cosmetic compositions of Examples 1 to 6 and Comparative Examples 1 to 12 was measured and the results are shown in Table 4 below. At this time, the viscosity was measured in 2 minutes at 12rpm with a spindle 3 using a Brookfield viscometer after all samples were left for about 2 hours at 30 ℃.
[시험예 2] 유화 안정도 측정 Test Example 2 Emulsion Stability Measurement
상기 실시예 1~6 및 비교예 1~12의 조성물의 유화 안정도를 판단하기 위하여 각 조성물 샘플을 45℃ 고온 항온조에 넣고 유화 제형의 수상과 유상이 분리되기까지 걸리는 시간을 측정하였다.In order to determine the emulsion stability of the compositions of Examples 1 to 6 and Comparative Examples 1 to 12, each composition sample was placed in a 45 ° C. high temperature thermostat and the time taken for the aqueous phase and the oil phase of the emulsion formulation to be separated was measured.
상기 표 4와 표 5에서 알 수 있듯이, 본 발명에 따라 제조한 프룩토오스 1,6-디포스페이트 화합물을 유효성분으로 함유하는 피부 외용제 조성물로서 세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트 계면활성제 조합을 포함하며, 증점제로서 폴리아크릴레이트크로스폴리머-6를 포함하는 화장료 조성물인 실시예 1~6의 경우에는 우수한 점증력과 함께 고온에서 2개월 이상 분리되지 않는 안정한 유화 제형이 형성된 것을 확인할 수 있는 것에 비해, 비교예 1~12의 경우 점증력이 실시예 1~6에 비해 현저히 낮을 뿐만 아니라 모든 샘플이 15일 이내에 유화 제형이 분리되는 불안정한 제형이 형성됨을 확인할 수 있었다.As can be seen in Table 4 and Table 5, cetearyl glucoside / inulin lauryl carbamate or sodium stea as a composition for external application containing a fructose 1,6-diphosphate compound prepared according to the present invention as an active ingredient In the case of Examples 1 to 6, which is a cosmetic composition containing a combination of a royl glutamate / glyceryl stearate citrate surfactant and comprising polyacrylate crosspolymer-6 as a thickener, at least two months at high temperature with excellent thickening power. Compared to Examples 1 to 6, the incremental strength was significantly lower than that of Examples 1 to 6, and the labile formulations in which the emulsion formulations were separated within 15 days were observed. It was confirmed that the formation.
Claims (8)
세테아릴글루코사이드 / 이눌린라우릴카바메이트 또는 소듐스테아로일글루타메이트 / 글리세릴스테아레이트시트레이트; 및
폴리아크릴레이트크로스폴리머-6를 포함하는 것을 특징으로 하는 피부 외용제 조성물Fructose 1,6-diphosphate;
Cetearylglucoside / inulinlaurylcarbamate or sodium stearoylglutamate / glycerylstearate citrate; And
A composition for external application of skin, comprising polyacrylate crosspolymer-6
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110126879A KR101480702B1 (en) | 2011-11-30 | 2011-11-30 | Cosmetic composition of oil in water type containing fructose 1,6-diphosphate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110126879A KR101480702B1 (en) | 2011-11-30 | 2011-11-30 | Cosmetic composition of oil in water type containing fructose 1,6-diphosphate |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130060682A true KR20130060682A (en) | 2013-06-10 |
KR101480702B1 KR101480702B1 (en) | 2015-01-09 |
Family
ID=48859066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20110126879A Active KR101480702B1 (en) | 2011-11-30 | 2011-11-30 | Cosmetic composition of oil in water type containing fructose 1,6-diphosphate |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101480702B1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051244A (en) | 1993-01-27 | 2000-04-18 | Perricone; Nicholas V. | Fructose diphosphate topical compositions |
KR100482667B1 (en) * | 2002-05-09 | 2005-04-13 | 주식회사 태평양 | Composition for external application to the skin containing D-Fructose 1,6 diphosphate |
KR100897908B1 (en) * | 2002-05-23 | 2009-05-18 | (주)아모레퍼시픽 | Skin external composition containing fructose 1,6-diphosphate or derivatives thereof to improve skin dryness |
KR101654576B1 (en) * | 2009-11-26 | 2016-09-23 | (주)아모레퍼시픽 | Nanoemulsion containing high content of hydrophobic ingredients and the method for preparing thereof |
-
2011
- 2011-11-30 KR KR20110126879A patent/KR101480702B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR101480702B1 (en) | 2015-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101060634B1 (en) | Skin external preparations containing phosphorylated sugars | |
US20140315995A1 (en) | Antioxidant Compositions and Methods of Using the Same | |
KR102006947B1 (en) | Cosmetics Compositions for antioxidant | |
KR101145060B1 (en) | O/W cosmetic composition having improved cosmetics formulation stability | |
JP2022550156A (en) | Punica granatum extract and its cosmetic use | |
ES2904592T3 (en) | Anti-aging agent and anti-aging composition for skin | |
KR101781466B1 (en) | Antioxidant composition for skin external application comprising nelumbo nucifera flowers extract and prunus mume fruits extract | |
JPH11246339A (en) | Preparation for external use for skin | |
CN105726351B (en) | Synergistic compositions, formulations and related methods for reducing ultraviolet-induced lipid peroxidation | |
JP2022138175A (en) | Composition for external use on the skin | |
KR102780293B1 (en) | Cosmetic composition comprising Actinidia fruit extract, actinidia flower extract and actinidia stem extract, and method for manufacturing the same | |
KR102473876B1 (en) | Composition for stabilizing vitamin-c and cosmetic composition comprising the same | |
KR20130060682A (en) | Cosmetic composition of oil in water type containing fructose 1,6-diphosphate | |
KR20100052092A (en) | Skin whitening cosmetics | |
KR101985886B1 (en) | Composition comprising indole compound and panthenol for preventing and improving skin damage caused by UV radiation | |
KR102499609B1 (en) | Rejuvenating emulsion type cosmetic composition and manufacturing method thereof | |
KR101923966B1 (en) | Composition containing ly294002 for skin whitening | |
JP7577499B2 (en) | External Composition | |
KR101873884B1 (en) | Skin-whitening composition containing esculin derivatives | |
KR101438376B1 (en) | Composition for skin external containing fructose 1,6-diphosphate stabilized by pH control | |
JP2011032182A (en) | Singlet oxygen quencher, and skin preparation for external use and cosmetic each comprising the same | |
KR20170143097A (en) | Functional cosmetic composition comprising phytosphingosine derivative | |
KR101928027B1 (en) | Composition for protection against UV-induced skin damages | |
KR20200020322A (en) | Cosmetic composition having anti oxidant, whitening, and anti aging activity | |
KR101785491B1 (en) | Rocket extract-containing ingredients stimulating hyaluronic acid synthesis and skin elasticity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20111130 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20130315 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20111130 Comment text: Patent Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140613 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20141120 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20150105 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20150106 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20171222 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20171222 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190102 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20190102 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20200102 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20201228 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20211221 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20231226 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20241223 Start annual number: 11 End annual number: 11 |